Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Breast Neoplasms: HELP
John M. S. Bartlett
Based on 94 articles published since 2007
||||
Expertise Level
The expertise of John M. S. Bartlett ranks in the
  • Top 0.019%
  • ... of 253,558 published authors worldwide on Breast Neoplasms
  • ... from 2007 through 2018
  • ... based on contributions to 94 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
 
Aliases Bartlett, John M S   ·   Bartlett, J M S
Work Locations
Details
Most likely:    University of Edinburgh      
2017
  • Li Ka Shing Centre, Cancer Research UK Cambridge Institute. · Department of Pathology. · Institute of Astronomy, University of Cambridge, Cambridge. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh. · Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge. · Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 28525534
  • EORTC Headquarters, Brussels, Belgium. · EORTC Headquarters, Brussels, Belgium. · Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt. · Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. · Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Pubmed 28324265
  • Transformative Pathology, Ontario Institute for Cancer Research (OICR), MaRS Centre, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Department of Pathology, Elizabeth University Hospital, 1345 Govan Road, Govan, Glasgow G51 4TF, UK. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Breast Center, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research SAKK, CH-9007 St. Gallen, Switzerland. Electronic address: · Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, Rotterdam 3008 AE, The Netherlands. Electronic address: · Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Division of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Leicester Clinical Trials Unit, University of Leicester, Leicester LE5 4PW, UK. Electronic address: · Surgical Oncology, University of Newcastle, Calvary Mater Newcastle Hospital, Locked Bag 7, HRMC, Newcastle, NSW 2310, Australia. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Academic Department of Biochemistry, Royal Marsden Hospital, and Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · Pubmed 28494403
  • Department of Oncology, University of Cambridge, Cambridge. · NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn. · Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge. · Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough. · Department of Oncology, Nottingham City Hospital, Nottingham. · Department of Oncology, West Middlesex University Hospital, Isleworth. · Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, UK. · Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada. · Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh. · Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Pathology, University of Edinburgh, Edinburgh, UK. · Pubmed 28459938
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · EORTC Headquarters, Brussels, Belgium. · Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. · Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. · Swedish Association of Breast Oncologists (SABO), Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. · Department of Oncology, Cheltenham General Hospital, Gloucestershire, UK. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland, UK. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: · Pubmed 28292559
2016
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON Canada. · Saint John Regional Hospital, Saint John, MB, Canada. · Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. · Pubmed 27056899
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
  • Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Immunology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James's University Hospital, Leeds, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Pubmed 26852132
2015
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh, UK. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James' University Hospital, Leeds, UK. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. · University of Toronto, Toronto, ON, Canada. · McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG] and Queen's University, Kingston, ON, Canada. · Pubmed 26372731
2014
  • Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP). · Pubmed 24402423
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. · Leiden University Medical Center, Leiden, The Netherlands. · Department of Gynecological Oncology, University Hospital, Freiburg, Germany. · Department of Surgery, Athens University Medical School, Athens, Greece. · Oncology Center, St Augustinus, Antwerp, Belgium. · Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. · 1] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK [2] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 25314051
2013
  • 1] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada M5G 0A3 [2] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK. · Pubmed 24091623
2011
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR, United Kingdom. · Pubmed 21422407
2010
  • Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University,Western General Hospital, Crewe Road South, Edinburgh, UK. · Pubmed 21115427
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK. · Pubmed 20615243
  • Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 20459530
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, UK. · Pubmed 20079691
2009
  • Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh EH4 2XR, England. · Pubmed 19762528
2016
  • From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany. · Pubmed 26717057
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Pubmed 27130929
2013
  • Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. · Pubmed 24203987
2012
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, UK. · Pubmed 22976805
  • Endocrine Cancer Group, Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 22644297
  • Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom. · Pubmed 22197227
  • Edinburgh Breakthrough Breast Cancer Unit, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 21638049
  • Breakthrough Breast Cancer, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 21390497
2011
  • Western General Hospital, Edinburgh, EH4 2XU, UK. · Pubmed 20941539
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, Scotland. · Pubmed 21757600
2010
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 20676126
  • Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK. · Pubmed 20480226
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Pubmed 20461093
  • School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK. · Pubmed 20181233
2009
  • Edinburgh Breakthrough Breast Cancer Research Unit, Endocrine Cancer Research Group, Western General Hospital, Edinburgh, UK. · Pubmed 19925033
  • Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK. · Pubmed 19845790
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 19242061
  • Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK. · Pubmed 19207951
Probable:    University of London      
2017
  • Transformative Pathology, Ontario Institute for Cancer Research (OICR), MaRS Centre, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Department of Pathology, Elizabeth University Hospital, 1345 Govan Road, Govan, Glasgow G51 4TF, UK. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Breast Center, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research SAKK, CH-9007 St. Gallen, Switzerland. Electronic address: · Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, Rotterdam 3008 AE, The Netherlands. Electronic address: · Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Division of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Leicester Clinical Trials Unit, University of Leicester, Leicester LE5 4PW, UK. Electronic address: · Surgical Oncology, University of Newcastle, Calvary Mater Newcastle Hospital, Locked Bag 7, HRMC, Newcastle, NSW 2310, Australia. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Academic Department of Biochemistry, Royal Marsden Hospital, and Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · Pubmed 28494403
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · EORTC Headquarters, Brussels, Belgium. · Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. · Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. · Swedish Association of Breast Oncologists (SABO), Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. · Department of Oncology, Cheltenham General Hospital, Gloucestershire, UK. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland, UK. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: · Pubmed 28292559
2016
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
2014
  • Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP). · Pubmed 24402423
  • Cancer Research UK Cambridge Institute Departments of Pathology Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge Strangeways Research Laboratory, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham. · University of Leeds and Leeds Cancer Research UK Centre, St James' Institute of Oncology, Leeds, UK. · Ontario Institute for Cancer Research, Toronto, Canada and Biomarker and Companion Diagnostics, Edinburgh Cancer Research Centre, Edinburgh Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Department of Pathology and Laboratory Medicine, University of British Columbia; Integrative Oncology Department, British Columbia Cancer Agency, Vancouver. · Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge · Pubmed 24915873
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. · Leiden University Medical Center, Leiden, The Netherlands. · Department of Gynecological Oncology, University Hospital, Freiburg, Germany. · Department of Surgery, Athens University Medical School, Athens, Greece. · Oncology Center, St Augustinus, Antwerp, Belgium. · Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. · 1] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK [2] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 25314051
2013
  • 1] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada M5G 0A3 [2] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK. · Pubmed 24091623
2016
  • From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany. · Pubmed 26717057
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Pubmed 27130929
2014
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24099077
  • Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's Hospital, King's College London School of Medicine, London, SE1 9RT, UK, · Pubmed 24519386
2013
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24101045
  • Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. · Pubmed 24203987
2010
  • Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK. · Pubmed 20480226
Probable:    Miscellaneous institutions in Toronto      
2017
  • Li Ka Shing Centre, Cancer Research UK Cambridge Institute. · Department of Pathology. · Institute of Astronomy, University of Cambridge, Cambridge. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh. · Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge. · Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 28525534
  • EORTC Headquarters, Brussels, Belgium. · EORTC Headquarters, Brussels, Belgium. · Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt. · Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. · Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Pubmed 28324265
  • Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK. · Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, LS9 7TF, UK. · Department of Radiation Oncology, Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, Netherlands. · Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, Netherlands. · Scottish Clinical Trials Research Unit, NHS National Services Scotland, Edinburgh, EH12 9EB, UK. · Centre of Population Health Sciences, Edinburgh University Medical School, Edinburgh, EH8 9AG, UK. · Edinburgh Cancer Centre, Western General Hospital, Edinburgh, EH4 2XU, UK. · Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada. · Beatson Oncology Centre, Gartnavel Campus, Glasgow, G12 0YN, UK. · Pubmed 28190252
  • Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic address: · Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK. · Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK. · Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. · Independent Cancer Patients' Voice, London, UK. · National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK. · University of Alberta, Edmonton, Alberta, Canada. · Pubmed 29241890
  • Department of Oncology, University of Cambridge, Cambridge. · NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn. · Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge. · Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough. · Department of Oncology, Nottingham City Hospital, Nottingham. · Department of Oncology, West Middlesex University Hospital, Isleworth. · Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, UK. · Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada. · Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh. · Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Pathology, University of Edinburgh, Edinburgh, UK. · Pubmed 28459938
  • Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. · Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Campus, Coventry CV4 7AL, UK. · Ontario Institute of Cancer Research, Toronto, Ontario M5G 0A3, Canada. · UCL-Advanced Diagnostics, University College London, 21 University Street, London WC1E 6JJ, UK. · Department of Pathology, University College London Hospitals, 235, Euston Road, London NW1 2BU, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, HA6 2RN, UK. · Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Department of Oncology, University College London Hospitals, London NW1 2PG, UK. · Pubmed 28222072
2016
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON Canada. · Saint John Regional Hospital, Saint John, MB, Canada. · Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. · Pubmed 27056899
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
  • Department of Oncology, University College London Hospitals, London, UK. · Warwick Medical School, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, ON, Canada. · Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. · School of Social and Community Medicine, University of Bristol, Bristol, UK. · Independent Cancer Patients' Voice, London, UK. · Research Oncology, Division of Cancer Studies, King's College London, London, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada. · Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundations Trust, Cambridge, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, UK. · Pubmed 26867046
  • Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Immunology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James's University Hospital, Leeds, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Pubmed 26852132
2015
  • Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Division of Cancer Studies, Department of Research Oncology, King's College London, London, UK. · Department of Transformative Pathology, Ontario Institute of Cancer Research, Toronto, Canada. · Department of Histopathology, UK NEQAS for Immunocytochemistry, University College London, London, UK. · Department of Cellular Pathology, Birmingham Heartlands Hospital, Birmingham, UK. · Department of Histopathology, Bradford Royal Infirmary, Bradford, UK. · Department of Histopathology, Addenbrookes Hospital, Cambridge, UK. · Department of Histopathology, Academic Unit of Pathology, St James's University Hospital, Leeds, UK. · Department of Histopathology, Countess of Chester Hospital, Chester, UK. · Pubmed 25488926
  • Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. · Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK. · Ontario Institute for Cancer Research, Toronto, ON, Canada. · Queen Elizabeth Hospital Birmingham, Birmingham, UK. · University College London Hospitals and Medical School, London, UK. · Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. · Pubmed 25585651
  • Department of Breast Surgery, Nuffield House University Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK. · Western General Hospital, Edinburgh, UK. · Sussex Health Outcomes, Research & Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9RX, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. · Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada. · Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, B15 2TT, UK. · Health Economics Unit, University of Birmingham, Birmingham, B15 2TT, UK. · St. James's Hospital, Leeds, UK. · Department of Histopathology, Academic Unit of Pathology, St James's University Hospital, Leeds, UK. · Division of Cancer Studies, Department of Research Oncology, King's College London, UK. · Ninewells Medical School, Dundee, DD1 9SY, UK. · University of Sussex, Brighton, BN1 9PX, UK. · Independent Cancer Patients Voices, London, EC1R 0LL. · Pubmed 26296293
  • Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. · Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy. · Department of Surgery and Cancer, Imperial College London, London. · Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool. · Institute of Cancer Research-Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Section of Oncology, Institute of Clinical Medicine, University of Bergen, Bergen Department of Oncology, Haukeland University Hospital, Bergen, Norway. · Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. · Department of Pathology, Herlev Hospital, Herlev, Denmark. · Department of Oncology, AZ Klina Hospital, Brasschaat, Belgium. · Department of Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. · Ontario Institute of Cancer Research, Toronto, Canada. · Department of Surgery and Cancer, Imperial College London, London · Pubmed 26002610
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh, UK. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James' University Hospital, Leeds, UK. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. · University of Toronto, Toronto, ON, Canada. · McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG] and Queen's University, Kingston, ON, Canada. · Pubmed 26372731
  • Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada. · Genetic Pathology Evaluation Centre, British Columbia (BC) Cancer Agency, Vancouver, British Columbia V5Z 1M9, Canada. · BC Cancer Agency, University of British Columbia, Vancouver, British Columbia V5Z 4E6, Canada. · NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada. · Saint John Regional Hospital, Saint John, New Brunswick E2L 4L4, Canada. · Juravinski Cancer Clinic, Hamilton Health Sciences, McMaster University, Hamilton, Ontario L8V 5C2, Canada. · Pubmed 26284338
  • Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD. · University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT. · University of Rochester Medical Center, Rochester, NY. · Stanford University Medical Center, Stanford, CA. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia. · St Jude Medical Center, Fullerton, CA. · Sunnybrook Health Sciences Center, Toronto, Ontario, Canada. · Mayo Clinic, Rochester, MN. · American Society of Clinical Oncology, Alexandria, VA. · National Adjuvant Surgical Breast and Bowel Project, Pittsburgh, PA. · Mayo Clinic, Jacksonville, FL. · University of Southern California, Los Angeles, CA. · North Carolina State University, Raleigh, NC. · Indiana University Medical Center, Indianapolis, IN. · University of Milan, European Institute of Oncology, Milan, Italy. · Royal Marsden Hospital, London, United Kingdom. · National Cancer Institute, Bethesda, MD. · University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 25753441
  • Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. · Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK. · Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · The Emmes Corporation, Rockville, Maryland, USA. · Indiana University Simon Cancer Center, Indianapolis, Indiana, USA. · Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, Ontario, Canada. · Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden. · Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York, USA. · Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. · PhenoPath Laboratories, Seattle, Washington, USA. · Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA. · Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada. · Department of Pathology, Kawasaki Medical School, Kurashiki City, Japan. · Department of Pathology, Hakuaikai Sagara Hospital, Matsubaracho, Kagoshima, Japan. · Department of Pathology, Centre Jean Perrin and Université d'Auvergne, Clermont-Ferrand, France. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan. · Institut Jules Bordet, Brussels, Belgium. · Birmingham Heart of England, National Health Service, Birmingham, UK. · Slagelse Hospital, Slagelse, Region Sjælland, Denmark. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy. · Academic Department of Biochemistry, Royal Marsden Hospital, London, UK. · Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA. · Pubmed 25698062
2014
  • Ontario Institute for Cancer Research, Toronto, ON, Canada; · Pubmed 24262106
2013
  • Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, ON M5G 0A3, Canada. · Pubmed 23535839
2012
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 23045591
2014
  • Ontario Institute for Cancer Research, Toronto, ON, Canada. · Pubmed 24267587
2012
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, ON, M5G 043, Canada. · Pubmed 22562124
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, Ontario, Canada M5G 043. · Pubmed 22430898
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 94 total) written by John M. S. Bartlett about Breast Neoplasms:

  • Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. 2017
  • Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. 2017
  • The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer. 2017
  • Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. 2017
  • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. 2017
  • Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. 2017
  • Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. 2017
  • Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. 2017
  • A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. 2016
  • Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. 2016
Show List of Full Article Records
Google Searches

Learn more about John M. S. Bartlett using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
University of Edinburgh
University of London
Miscellaneous institutions in Toronto
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
University of Edinburgh
2017
  • Li Ka Shing Centre, Cancer Research UK Cambridge Institute. · Department of Pathology. · Institute of Astronomy, University of Cambridge, Cambridge. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh. · Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge. · Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 28525534
  • EORTC Headquarters, Brussels, Belgium. · EORTC Headquarters, Brussels, Belgium. · Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt. · Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. · Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Pubmed 28324265
  • Transformative Pathology, Ontario Institute for Cancer Research (OICR), MaRS Centre, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Department of Pathology, Elizabeth University Hospital, 1345 Govan Road, Govan, Glasgow G51 4TF, UK. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Breast Center, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research SAKK, CH-9007 St. Gallen, Switzerland. Electronic address: · Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, Rotterdam 3008 AE, The Netherlands. Electronic address: · Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Division of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Leicester Clinical Trials Unit, University of Leicester, Leicester LE5 4PW, UK. Electronic address: · Surgical Oncology, University of Newcastle, Calvary Mater Newcastle Hospital, Locked Bag 7, HRMC, Newcastle, NSW 2310, Australia. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Academic Department of Biochemistry, Royal Marsden Hospital, and Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · Pubmed 28494403
  • Department of Oncology, University of Cambridge, Cambridge. · NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn. · Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge. · Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough. · Department of Oncology, Nottingham City Hospital, Nottingham. · Department of Oncology, West Middlesex University Hospital, Isleworth. · Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, UK. · Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada. · Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh. · Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Pathology, University of Edinburgh, Edinburgh, UK. · Pubmed 28459938
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · EORTC Headquarters, Brussels, Belgium. · Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. · Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. · Swedish Association of Breast Oncologists (SABO), Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. · Department of Oncology, Cheltenham General Hospital, Gloucestershire, UK. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland, UK. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: · Pubmed 28292559
2016
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON Canada. · Saint John Regional Hospital, Saint John, MB, Canada. · Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. · Pubmed 27056899
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
  • Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Immunology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James's University Hospital, Leeds, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Pubmed 26852132
2015
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh, UK. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James' University Hospital, Leeds, UK. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. · University of Toronto, Toronto, ON, Canada. · McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG] and Queen's University, Kingston, ON, Canada. · Pubmed 26372731
2014
  • Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP). · Pubmed 24402423
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. · Leiden University Medical Center, Leiden, The Netherlands. · Department of Gynecological Oncology, University Hospital, Freiburg, Germany. · Department of Surgery, Athens University Medical School, Athens, Greece. · Oncology Center, St Augustinus, Antwerp, Belgium. · Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. · 1] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK [2] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 25314051
2013
  • 1] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada M5G 0A3 [2] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK. · Pubmed 24091623
2011
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR, United Kingdom. · Pubmed 21422407
2010
  • Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University,Western General Hospital, Crewe Road South, Edinburgh, UK. · Pubmed 21115427
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK. · Pubmed 20615243
  • Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 20459530
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, UK. · Pubmed 20079691
2009
  • Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh EH4 2XR, England. · Pubmed 19762528
2016
  • From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany. · Pubmed 26717057
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Pubmed 27130929
2013
  • Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. · Pubmed 24203987
2012
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, UK. · Pubmed 22976805
  • Endocrine Cancer Group, Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 22644297
  • Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom. · Pubmed 22197227
  • Edinburgh Breakthrough Breast Cancer Unit, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 21638049
  • Breakthrough Breast Cancer, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. · Pubmed 21390497
2011
  • Western General Hospital, Edinburgh, EH4 2XU, UK. · Pubmed 20941539
  • Endocrine Cancer Group, Edinburgh University, Edinburgh, Scotland. · Pubmed 21757600
2010
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 20676126
  • Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK. · Pubmed 20480226
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Pubmed 20461093
  • School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK. · Pubmed 20181233
2009
  • Edinburgh Breakthrough Breast Cancer Research Unit, Endocrine Cancer Research Group, Western General Hospital, Edinburgh, UK. · Pubmed 19925033
  • Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK. · Pubmed 19845790
  • Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Pubmed 19242061
  • Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK. · Pubmed 19207951
University of London
2017
  • Transformative Pathology, Ontario Institute for Cancer Research (OICR), MaRS Centre, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Department of Pathology, Elizabeth University Hospital, 1345 Govan Road, Govan, Glasgow G51 4TF, UK. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Breast Center, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research SAKK, CH-9007 St. Gallen, Switzerland. Electronic address: · Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, Rotterdam 3008 AE, The Netherlands. Electronic address: · Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Division of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: · Leicester Clinical Trials Unit, University of Leicester, Leicester LE5 4PW, UK. Electronic address: · Surgical Oncology, University of Newcastle, Calvary Mater Newcastle Hospital, Locked Bag 7, HRMC, Newcastle, NSW 2310, Australia. Electronic address: · Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: · Academic Department of Biochemistry, Royal Marsden Hospital, and Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address: · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: · Pubmed 28494403
  • Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · EORTC Headquarters, Brussels, Belgium. · Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. · Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. · Swedish Association of Breast Oncologists (SABO), Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. · Department of Oncology, Cheltenham General Hospital, Gloucestershire, UK. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. · Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands. · Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland, UK. · BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: · Pubmed 28292559
2016
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
2014
  • Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP). · Pubmed 24402423
  • Cancer Research UK Cambridge Institute Departments of Pathology Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge Strangeways Research Laboratory, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham. · University of Leeds and Leeds Cancer Research UK Centre, St James' Institute of Oncology, Leeds, UK. · Ontario Institute for Cancer Research, Toronto, Canada and Biomarker and Companion Diagnostics, Edinburgh Cancer Research Centre, Edinburgh Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Department of Pathology and Laboratory Medicine, University of British Columbia; Integrative Oncology Department, British Columbia Cancer Agency, Vancouver. · Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge · Pubmed 24915873
  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. · Leiden University Medical Center, Leiden, The Netherlands. · Department of Gynecological Oncology, University Hospital, Freiburg, Germany. · Department of Surgery, Athens University Medical School, Athens, Greece. · Oncology Center, St Augustinus, Antwerp, Belgium. · Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. · 1] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK [2] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 25314051
2013
  • 1] Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada M5G 0A3 [2] Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK. · Pubmed 24091623
2016
  • From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany. · Pubmed 26717057
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Pubmed 27130929
2014
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24099077
  • Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's Hospital, King's College London School of Medicine, London, SE1 9RT, UK, · Pubmed 24519386
2013
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24101045
  • Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. · Pubmed 24203987
2010
  • Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK. · Pubmed 20480226
Miscellaneous institutions in Toronto
2017
  • Li Ka Shing Centre, Cancer Research UK Cambridge Institute. · Department of Pathology. · Institute of Astronomy, University of Cambridge, Cambridge. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh. · Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge. · Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Canada. · Pubmed 28525534
  • EORTC Headquarters, Brussels, Belgium. · EORTC Headquarters, Brussels, Belgium. · Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt. · Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. · Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. · University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK. · Pubmed 28324265
  • Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK. · Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, LS9 7TF, UK. · Department of Radiation Oncology, Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, Netherlands. · Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, Netherlands. · Scottish Clinical Trials Research Unit, NHS National Services Scotland, Edinburgh, EH12 9EB, UK. · Centre of Population Health Sciences, Edinburgh University Medical School, Edinburgh, EH8 9AG, UK. · Edinburgh Cancer Centre, Western General Hospital, Edinburgh, EH4 2XU, UK. · Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada. · Beatson Oncology Centre, Gartnavel Campus, Glasgow, G12 0YN, UK. · Pubmed 28190252
  • Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic address: · Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK. · Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK. · Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. · Independent Cancer Patients' Voice, London, UK. · National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK. · University of Alberta, Edmonton, Alberta, Canada. · Pubmed 29241890
  • Department of Oncology, University of Cambridge, Cambridge. · NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn. · Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge. · Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough. · Department of Oncology, Nottingham City Hospital, Nottingham. · Department of Oncology, West Middlesex University Hospital, Isleworth. · Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole. · Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, UK. · Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada. · Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh. · Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge. · Department of Pathology, University of Edinburgh, Edinburgh, UK. · Pubmed 28459938
  • Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. · Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Campus, Coventry CV4 7AL, UK. · Ontario Institute of Cancer Research, Toronto, Ontario M5G 0A3, Canada. · UCL-Advanced Diagnostics, University College London, 21 University Street, London WC1E 6JJ, UK. · Department of Pathology, University College London Hospitals, 235, Euston Road, London NW1 2BU, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, HA6 2RN, UK. · Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Department of Oncology, University College London Hospitals, London NW1 2PG, UK. · Pubmed 28222072
2016
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON Canada. · Saint John Regional Hospital, Saint John, MB, Canada. · Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. · Pubmed 27056899
  • Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 27384960
  • Department of Oncology, University College London Hospitals, London, UK. · Warwick Medical School, University of Warwick, Coventry, UK. · Ontario Institute for Cancer Research, Toronto, ON, Canada. · Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. · School of Social and Community Medicine, University of Bristol, Bristol, UK. · Independent Cancer Patients' Voice, London, UK. · Research Oncology, Division of Cancer Studies, King's College London, London, UK. · Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK. · Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada. · Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundations Trust, Cambridge, UK. · Department of Clinical Oncology, Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, UK. · Pubmed 26867046
  • Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Immunology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James's University Hospital, Leeds, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Pubmed 26852132
2015
  • Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Division of Cancer Studies, Department of Research Oncology, King's College London, London, UK. · Department of Transformative Pathology, Ontario Institute of Cancer Research, Toronto, Canada. · Department of Histopathology, UK NEQAS for Immunocytochemistry, University College London, London, UK. · Department of Cellular Pathology, Birmingham Heartlands Hospital, Birmingham, UK. · Department of Histopathology, Bradford Royal Infirmary, Bradford, UK. · Department of Histopathology, Addenbrookes Hospital, Cambridge, UK. · Department of Histopathology, Academic Unit of Pathology, St James's University Hospital, Leeds, UK. · Department of Histopathology, Countess of Chester Hospital, Chester, UK. · Pubmed 25488926
  • Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. · Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK. · Ontario Institute for Cancer Research, Toronto, ON, Canada. · Queen Elizabeth Hospital Birmingham, Birmingham, UK. · University College London Hospitals and Medical School, London, UK. · Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. · Pubmed 25585651
  • Department of Breast Surgery, Nuffield House University Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK. · Western General Hospital, Edinburgh, UK. · Sussex Health Outcomes, Research & Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9RX, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. · Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada. · Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, B15 2TT, UK. · Health Economics Unit, University of Birmingham, Birmingham, B15 2TT, UK. · St. James's Hospital, Leeds, UK. · Department of Histopathology, Academic Unit of Pathology, St James's University Hospital, Leeds, UK. · Division of Cancer Studies, Department of Research Oncology, King's College London, UK. · Ninewells Medical School, Dundee, DD1 9SY, UK. · University of Sussex, Brighton, BN1 9PX, UK. · Independent Cancer Patients Voices, London, EC1R 0LL. · Pubmed 26296293
  • Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. · Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy. · Department of Surgery and Cancer, Imperial College London, London. · Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool. · Institute of Cancer Research-Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Section of Oncology, Institute of Clinical Medicine, University of Bergen, Bergen Department of Oncology, Haukeland University Hospital, Bergen, Norway. · Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. · Department of Pathology, Herlev Hospital, Herlev, Denmark. · Department of Oncology, AZ Klina Hospital, Brasschaat, Belgium. · Department of Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. · Ontario Institute of Cancer Research, Toronto, Canada. · Department of Surgery and Cancer, Imperial College London, London · Pubmed 26002610
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Crewe Road South, Edinburgh, UK. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James' University Hospital, Leeds, UK. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. · University of Toronto, Toronto, ON, Canada. · McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG] and Queen's University, Kingston, ON, Canada. · Pubmed 26372731
  • Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada. · Genetic Pathology Evaluation Centre, British Columbia (BC) Cancer Agency, Vancouver, British Columbia V5Z 1M9, Canada. · BC Cancer Agency, University of British Columbia, Vancouver, British Columbia V5Z 4E6, Canada. · NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada. · Saint John Regional Hospital, Saint John, New Brunswick E2L 4L4, Canada. · Juravinski Cancer Clinic, Hamilton Health Sciences, McMaster University, Hamilton, Ontario L8V 5C2, Canada. · Pubmed 26284338
  • Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD. · University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT. · University of Rochester Medical Center, Rochester, NY. · Stanford University Medical Center, Stanford, CA. · Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia. · St Jude Medical Center, Fullerton, CA. · Sunnybrook Health Sciences Center, Toronto, Ontario, Canada. · Mayo Clinic, Rochester, MN. · American Society of Clinical Oncology, Alexandria, VA. · National Adjuvant Surgical Breast and Bowel Project, Pittsburgh, PA. · Mayo Clinic, Jacksonville, FL. · University of Southern California, Los Angeles, CA. · North Carolina State University, Raleigh, NC. · Indiana University Medical Center, Indianapolis, IN. · University of Milan, European Institute of Oncology, Milan, Italy. · Royal Marsden Hospital, London, United Kingdom. · National Cancer Institute, Bethesda, MD. · University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 25753441
  • Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. · Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK. · Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · The Emmes Corporation, Rockville, Maryland, USA. · Indiana University Simon Cancer Center, Indianapolis, Indiana, USA. · Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, Ontario, Canada. · Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden. · Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York, USA. · Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. · PhenoPath Laboratories, Seattle, Washington, USA. · Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA. · Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada. · Department of Pathology, Kawasaki Medical School, Kurashiki City, Japan. · Department of Pathology, Hakuaikai Sagara Hospital, Matsubaracho, Kagoshima, Japan. · Department of Pathology, Centre Jean Perrin and Université d'Auvergne, Clermont-Ferrand, France. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan. · Institut Jules Bordet, Brussels, Belgium. · Birmingham Heart of England, National Health Service, Birmingham, UK. · Slagelse Hospital, Slagelse, Region Sjælland, Denmark. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy. · Academic Department of Biochemistry, Royal Marsden Hospital, London, UK. · Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA. · Pubmed 25698062
2014
  • Ontario Institute for Cancer Research, Toronto, ON, Canada; · Pubmed 24262106
2013
  • Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, ON M5G 0A3, Canada. · Pubmed 23535839
2012
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · Pubmed 23045591
2014
  • Ontario Institute for Cancer Research, Toronto, ON, Canada. · Pubmed 24267587
2012
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, ON, M5G 043, Canada. · Pubmed 22562124
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, Ontario, Canada M5G 043. · Pubmed 22430898
University of Toronto
2016
  • Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Informatics and Bio-Computing, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada. · NCIC Clinical Trials Group (NCIC CTG) and Queen's University, Kingston, ON, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON Canada. · Saint John Regional Hospital, Saint John, MB, Canada. · Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada. · Edinburgh Cancer Research UK Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. · Pubmed 27056899
  • Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Immunology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. · Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada. · Leeds Institute of Cancer and Pathology and Cancer Research UK Centre, St James's University Hospital, Leeds, UK. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. · Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. · Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, ON, M5G 0A3, Canada. · Pubmed 26852132
2014
  • Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP). · Pubmed 24402423
2016
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS). · Pubmed 27130929
2014
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24099077
2013
  • Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. · Pubmed 24101045
2012
  • Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. · Pubmed 22042366
Nottingham University Hospitals NHS Trust
2014
  • Cancer Research UK Cambridge Institute Departments of Pathology Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge Strangeways Research Laboratory, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham. · University of Leeds and Leeds Cancer Research UK Centre, St James' Institute of Oncology, Leeds, UK. · Ontario Institute for Cancer Research, Toronto, Canada and Biomarker and Companion Diagnostics, Edinburgh Cancer Research Centre, Edinburgh Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Department of Pathology and Laboratory Medicine, University of British Columbia; Integrative Oncology Department, British Columbia Cancer Agency, Vancouver. · Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge · Pubmed 24915873
University of Nottingham
2014
  • Cancer Research UK Cambridge Institute Departments of Pathology Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge Strangeways Research Laboratory, Cambridge. · Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge. · Warwick Clinical Trials Unit, University of Warwick, Coventry. · Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham. · University of Leeds and Leeds Cancer Research UK Centre, St James' Institute of Oncology, Leeds, UK. · Ontario Institute for Cancer Research, Toronto, Canada and Biomarker and Companion Diagnostics, Edinburgh Cancer Research Centre, Edinburgh Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK. · Department of Pathology and Laboratory Medicine, University of British Columbia; Integrative Oncology Department, British Columbia Cancer Agency, Vancouver. · Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. · Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge · Pubmed 24915873
Miscellaneous institutions in Edinburgh
2011
2009
  • Division of Pathology, Edinburgh Cancer Research Centre, Edinburgh, Scotland. · Pubmed 19912364
46 Other Locations Show
Yearly article counts 086910121413111010
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.